Home > Cardiology > AHA 2020 > Heart Failure > Dapagliflozin reduces renal risk independent of CV disease status

Dapagliflozin reduces renal risk independent of CV disease status

Presented By
Prof. John McMurray, University of Glasgow, Scotland
Conference
AHA 2020
Trial
DAPA-CKD

A new analysis from the DAPA-CKD trial found that the SGLT2 inhibitor dapagliflozin reduced the risk of kidney failure, death from cardiovascular causes or hospitalisation for heart failure, and prolonged survival in people with chronic kidney disease (CKD), with or without type 2 diabetes mellitus (T2DM). The benefits of dapagliflozin were independent of the presence of cardiovascular disease (CVD) [1,2].

Prof. John McMurray (University of Glasgow, Scotland) presented a new analysis of the randomised, double-blind, placebo-controlled DAPA-CKD trial (NCT03036150), which enrolled 4,304 patients to assess the impact of dapagliflozin 10 mg versus placebo alongside standard of care (i.e. ACE inhibitor or ARB) [1]. Participants had a urinary albumin to creatinine ratio of ≥200 mg/g and an estimated glomerular filtration rate (eGFR) between 25–75 mL/min/1.73 m2



Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on